Skip to main content
SpringerLink
Log in

Treatment

  • Chapter
Clinicians’ Guide to Helicobacter pylori

  • 45 Accesses

Abstract

Eradication of H. pylori is a major advance in the management of gastroduodenal diseases. About 95% of peptic ulcers in patients who are not taking NSAIDs are due to H. pylori and these ulcers heal faster and are permanently cured by successful eradication therapy (Chapter 3). The same therapy can also heal some lymphomas and may well decrease the risk of gastric cancer if it is given early enough. The development of regimens has progressed at an impressive rate, for example, studies have shown that H. pylori can be eradicated from over 90% of individuals by prescribing three capsules and two tablets daily for one week — omeprazole 20 mg, clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. [1] (For further examples see below [1])! However it is currently fashionable to criticize the way in which this achievement has come about. The Americans in particular regard the process with amusement as ‘a European cottage industry’. Unfortunately they have been unable to contribute themselves, largely because their lawyers are out of control.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bazzoli F, Zagari RM, Fossi S et al. Short-term, low-dose triple therapy for eradication of Helicobacter pyloriEur J Gastroenterol Hepatol 1994; 6: 773–777.

    Article  Google Scholar 

  2. Gough KR, Korman MG, Bardhan KD et al. Ranitidine and Cimetidine in prevention of duodenal ulcer relapse. A double-blind, randomised, multicentre, comparative trial. Lancet 1984; ii: 659–662.

    Article  Google Scholar 

  3. Graham DY, Lew GM, Klein PD et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992; 116: 705–708.

    Article  PubMed  CAS  Google Scholar 

  4. Sarosiek J, Roche JK, Marshall B, McCallum RW. Urease enzyme inhibition by bismuth subsalicylate; a putative antibacterial mechanism. Gastroenterology 1990; 98: Al 19.

    Google Scholar 

  5. Nagata K, Satoh H, Iwahi T et al. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother 1993; 37: 769–774.

    Article  PubMed  CAS  Google Scholar 

  6. Logan RPH, Walker MM, Misiewicz JJ et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995; 36:12–16.

    Article  PubMed  CAS  Google Scholar 

  7. Ferguson DA, Jr., Li C, Patel NR, Mayberry WR, Chi DS, Thomas E. Isolation of Helicobacter pylori from saliva. J Clin Microbiol 1993; 31:2802–2804.

    PubMed  Google Scholar 

  8. Gavey CJ, Szeto ML, Nwokolo CU et al. Bismuth accumulates in the body during treatment with tripotassium dicitrato bismuthate. Aliment Pharmacol Ther 1989; 3: 21–28.

    Article  PubMed  CAS  Google Scholar 

  9. Marshall BJ, Goodwin CS, Warren JR et al Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; ii: 1437–1442.

    Article  Google Scholar 

  10. Hentschel E, Brandstatter G, Dragosics B et al Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328:308–312.

    Article  PubMed  CAS  Google Scholar 

  11. Parsonnet J, Blaser MJ, Perez Perez GI et al. Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. Gastroenterology 1992; 102: 41–46.

    PubMed  CAS  Google Scholar 

  12. Kuipers EJ, Pena AS, Van Kamp G et al. Seroconversion for Helicobacter pylori. Lancet 1993; 342:328–331.

    Article  PubMed  CAS  Google Scholar 

  13. Atherton JC, Spiller RC. The urea breath test for Helicobacter pylori. Gut 1994; 35: 723–725.

    Article  PubMed  CAS  Google Scholar 

  14. Kosunen TU, Seppala K, Sarna S, Sipponen P. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet 1992; 339: 893–895.

    Article  PubMed  CAS  Google Scholar 

  15. Hirschl AM, Brandstatter G, Dragosics B et al. Kinetics of specific IgG antibodies for monitoring the effect of anti-Helicobacter pylori chemotherapy. J Infect Dis 1993; 168: 763–766.

    Article  PubMed  CAS  Google Scholar 

  16. Tytgat GNJ, Axon ATR, Dixon MF et al. Helicobacter pylori: causal agent in peptic ulcer disease? In: Anonymous SPI, ed. Working Party Reports. Melbourne: Blackwell Scientific Publications, 1990:36–45.

    Google Scholar 

  17. Graham DY, Lew GM, Malaty HM et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102:493–496.

    PubMed  CAS  Google Scholar 

  18. Labenz J, Leverkus F, Madeya S et al. Omeprazole plus amoxycillin for cure of H. pylori infection: factors influencing the treatment success (abstract). Scand J Gastroenterol 1994; 29: 1070–1075.

    Article  PubMed  CAS  Google Scholar 

  19. Harries AD, Stewart M, Deegan KM et al. Helicobacter pylori in Malawi, central Africa. J Infect 1992; 24:269–276.

    Article  PubMed  CAS  Google Scholar 

  20. Anonymous. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992; 11: 777–781.

    Google Scholar 

  21. Logan RP, Gummett PA, Misiewicz JJ et al One week’s anti-Helicobacter pylori treatment for duodenal ulcer. Gut 1994; 35: 15–18.

    Article  PubMed  CAS  Google Scholar 

  22. Logan RP, Gummett PA, Schaufelberger HD et al Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994;35:323–326.

    Article  PubMed  CAS  Google Scholar 

  23. Peterson WL, Graham DY, Marshall B et al Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol 1993; 88: 1860–1864.

    PubMed  CAS  Google Scholar 

  24. Rautelin H, Tee W, Seppala K, Kosunen TU. Ribotyping patterns and emergence of metronidazole resistance in paired clinical samples of Helicobacter pyloriJ Clin Microbiol 1994; 32: 1079–1082.

    PubMed  CAS  Google Scholar 

  25. Savarino V, Mela GS, Zentilin P et al Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy. Dig Dis Sci 1994; 39:161–168.

    Article  PubMed  CAS  Google Scholar 

  26. Andersson T, Cederberg C, Edvardsson G et al Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990;47:79–85.

    Article  PubMed  CAS  Google Scholar 

  27. Lind T, Cederberg C, Ekenved G et al Effect of omeprazole — a gastric proton pump inhibitor — on pentagastrin stimulated acid secretion in man. Gut 1983; 24: 270–276.

    Article  PubMed  CAS  Google Scholar 

  28. Anonymous. Metronidazole. In: Dollery CT, ed. Therapeutic drugs. Edinburgh: Churchill Livingstone, 1991: M170-M176.

    Google Scholar 

  29. De Giacomo C, Fiocca R, Villani L et alHelicobacter pylori infection and chronic gastritis: clinical, serological, and histologic correlations in children treated with amoxicillin and colloidal bismuth subcitrate. J Pediatr Gastroenterol Nutr 1990; 11: 310–316.

    Article  PubMed  Google Scholar 

  30. Mahony MJ, Wyatt JI, Littlewood JM. Management and response to treatment of Helicobacter pylori gastritis. Arch Dis Child 1992; 67:940–943.

    Article  PubMed  CAS  Google Scholar 

  31. Israel DM, Hassall E. Treatment and long-term follow-up of Helicobacter pylori-associated duodenal ulcer disease in children. J Pediatr 1993; 123:53–58.

    Article  PubMed  CAS  Google Scholar 

  32. Atherton JC, Cockayne A, Balsitis M et al Detection of the intragastric sites at which Helicobacter pylori evades treatment with amoxycillin and Cimetidine. Gut 1995; 36: 670–4

    Article  PubMed  CAS  Google Scholar 

  33. Cooreman MP, Krausgrill P, Hengels KJ. Local gastric and serum amoxicillin concentrations after different oral application forms. Antimicrob Agents Chemother 1993; 37: 1506–1509.

    Article  PubMed  CAS  Google Scholar 

  34. Desai HG, Gill HH, Shankaran K et al Dental plaque: a permanent reservoir of Helicobacterpylori? Scand J Gastroenterol 1991;26:1205–1208.

    Article  PubMed  CAS  Google Scholar 

  35. De Cothi GA, Newbold KM, O’Connor HJ. Campylobacter-like organisms and heterotopic gastric mucosa in Meckel’s diverticula. J Clin Pathol 1989; 42:132–134.

    Article  PubMed  Google Scholar 

  36. Dye KR, Marshall BJ, Frierson HF Jr et al. Campylobacter pylori colonizing heterotopic gastric tissue in the rectum. Am J Clin Pathol 1990; 93:144–147.

    PubMed  CAS  Google Scholar 

  37. Atherton JC, Cullun DJE, Hawkey CJ, Spiller RC. Enhanced eradication of Helicobacter pylori by pre- versus postprandial amoxycillin suspension with omeprazole: implications for mode of action (abstract). Gastroenterology 1994; 106: A41

    Google Scholar 

  38. Atherton JC, Hudson N, Kirk GE et al. Amoxycillin capsules with omeprazole for the eradication of Helicobacter pylori. Assessment of the importance of antibiotic dose timing in relation to meals. Aliment Pharmacol Ther 1994; 8:495–498.

    Article  PubMed  CAS  Google Scholar 

  39. Weil J, Bell GD, Powell K et alHelicobacter pylori: treatment with combinations of pivampicillin and tripotassium dicitrato bismuthate. Aliment Pharmacol Ther 1991; 5:543–547.

    Article  PubMed  CAS  Google Scholar 

  40. Harris A, Misiewicz JJ. Eradication of H. pylori. In: Calam J, ed. Bailliere’s Clinical Gastroenterology: Helicobacter pylori. London: Baillière Tindall, 1995: (in press).

    Google Scholar 

  41. Prewett EJ, Luk YW, Fraser AG et al Comparison of one-day oral dosing with three bismuth compounds for the suppression of Helicobacter pylori assessed by the 13C-urea breath test. Aliment Pharmacol Ther 1992; 6:97–102.

    Article  PubMed  CAS  Google Scholar 

  42. Gorbach SL. Bismuth therapy in gastrointestinal diseases. Gastroenterology 1990; 99:863–875.

    PubMed  CAS  Google Scholar 

  43. Wagstaff AJ, Benfield P, Monk JP. Colloidal bismuth sub-citrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988; 36:132–157.

    Article  PubMed  CAS  Google Scholar 

  44. Tytgat GN. Bismuth is better. Scand J Gastroenterol Suppl 1988; 155:16–17.

    Article  PubMed  CAS  Google Scholar 

  45. Baron JH, Barr J, Batten J et al Acid, pepsin, and mucus secretion in patients with gastric and duodenal ulcer before and after colloidal bismuth subcitrate (De-Nol). Gut 1986; 27:486–490.

    Article  PubMed  CAS  Google Scholar 

  46. De Beaux AC, Defize J, Hunt RH. The effect of tripotassium dicitrato bismuthate on pepsin activity. Aliment Pharmacol Ther 1989;3:381–385.

    Article  PubMed  Google Scholar 

  47. Moshal MG, Gregory MA, Pillay C, Spitaels JM. Does the duodenal cell ever return to normal? A comparison between treatment with Cimetidine and DeNol. Scand J Gastroenterol Suppl 1979; 54:48–51.

    PubMed  CAS  Google Scholar 

  48. Martin DF, Hollanders D, May SJ et al. Difference in relapse rates of duodenal ulcer after healing with Cimetidine or tripotassium dicitrato bismuthate. Lancet 1981; i: 7–10.

    Article  Google Scholar 

  49. Lane MR, Lee SP. Recurrence of duodenal ulcer after medical treatment [published erratum appears in Lancet 1988; ii: 118]. Lancet 1988; i: 1147–1149.

    Google Scholar 

  50. Axon AT. Campylobacter pylori — therapy review. Scand J Gastroenterol Suppl 1989; 160: 35–38.

    Article  PubMed  CAS  Google Scholar 

  51. Nwokolo CU, Prewett EJ, Sawyerr AM et al. The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds. Gastroenterology 1991; 101: 889–894.

    PubMed  CAS  Google Scholar 

  52. Nwokolo CU, Lewin JF, Hudson M, Pounder RE. Trans-mucosal penetration of bismuth particles in the human stomach. Gastroenterology 1992; 102:163–167.

    PubMed  CAS  Google Scholar 

  53. Madaus S, Schulte Frohlinde E, Scherer C et al. Comparison of plasma bismuth levels after oral dosing with basic bismuth carbonate or tripotassium dicitrato bismuthate [published erratum appears in Aliment Pharmacol Ther 1992; 6: 761]. Aliment Pharmacol Ther 1992; 6:241–249.

    Google Scholar 

  54. Anonymous. Idiosyncratic neurotoxicity: clioquinol and bismuth [editorial]. Lancet 1980; i: 857–858.

    Google Scholar 

  55. Playford RJ, Matthews CH, Campbell MJ et al. Bismuth induced encephalopathy caused by tripotassium dicitrato bismuthate in a patient with chronic renal failure. Gut 1990; 31: 359–360.

    Article  PubMed  CAS  Google Scholar 

  56. Shamburek RD, Schubert ML. Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K(+)-ATPase inhibitors. Gastroenterol Clin N Am 1992; 21:527–550.

    CAS  Google Scholar 

  57. Lanzon Miller S, Pounder RE, Hamilton MR et al. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1987; 1:239–251.

    Article  PubMed  CAS  Google Scholar 

  58. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RCJ. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8:888–889.

    Article  PubMed  CAS  Google Scholar 

  59. Goodwin CS and McNulty CAM. Bacteriological and pharmacological basis for the treatment of Helicobacter pylori infection. In: Rathbone BJ, Heatley RV, eds. Helicobacter pylori and gas-troduodenal disease. Oxford: Blackwell Scientific Publications, 1992:224–231.

    Google Scholar 

  60. Marshall BJ, Barrett LJ, Prakash C et al Urea protects Helicobacter (Campylobacter) pylori from the bactericidal effect of acid. Gastroenterology 1990; 99:697–702.

    PubMed  CAS  Google Scholar 

  61. Iwahi T, Satoh H, Nakao M et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991; 35:490–496.

    Article  PubMed  CAS  Google Scholar 

  62. Mauch F, Bode G, Malfertheiner P. Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors (letter). Am J Gastroenterol 1993; 88:1801–1802.

    PubMed  CAS  Google Scholar 

  63. Sjostrom J-E, Berglund M-L, Fryklund J et al. Factors affecting the antibacterial activity of omeprazole and structural analogues in vitro (abstract). Acta Gastroenterol Belg 1993; 56(suppl): 144.

    Google Scholar 

  64. Wilde MI, McTavish D. Omeprazole. Drugs 1994; 48: 91–132.

    Article  PubMed  CAS  Google Scholar 

  65. Loft S, Poulsen HE, Sonne J, Dossing M. Metronidazole clearance: a one-sample method and influencing factors. Clin Pharmacol Ther 1988; 43:420–428.

    Article  PubMed  CAS  Google Scholar 

  66. Van Zanten SJ, Goldie J, Hollingsworth J et al. Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori. J Clin Pathol 1992;45:225–227.

    Article  PubMed  Google Scholar 

  67. Goodwin CS, Marshall BJ, Blincow ED et al. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol 1988; 41:207–210.

    Article  PubMed  CAS  Google Scholar 

  68. Lacey SL, Moss SF, Taylor GW. Metronidazole uptake by sensitive and resistant isolates of Helicobacter pyloriJ Antimicrob Chemother 1993; 32:393–400.

    Article  PubMed  CAS  Google Scholar 

  69. Rauws EA, Langenberg W, Houthoff HJ et al. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988; 94: 33–40.

    PubMed  CAS  Google Scholar 

  70. Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pyloriAm J Gastroenterol 1992; 87:1716–1727.

    PubMed  CAS  Google Scholar 

  71. Unge P, Gad A, Erilsson K et al Amoxycillin added to omeprazole prevents ulcer relapse in the treatment of duodenal ulcer patients. Eur J Gastroenterol Hepatol 1993; 5:325–331.

    Article  Google Scholar 

  72. McNulty CA, Dent JC, Ford GA, Wilkinson SP. Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother 1988; 22: 729–738.

    Article  PubMed  CAS  Google Scholar 

  73. Ericsson CD, Feldman S, Pickering LK, Cleary TG. Influence of subsalicylate bismuth on absorption of doxycycline. JAMA 1982;247:2266–2267.

    Article  PubMed  CAS  Google Scholar 

  74. Unge P, Gnarpe H. Pharmacokinetic, bacteriological and clinical aspects on the use of doxycycline in patients with active duodenal ulcer associated with Campylobacter pylori. Scand J Infect Dis Suppl 1988; 53: 70–73.

    PubMed  CAS  Google Scholar 

  75. Hardy DJ, Hanson CW, Hensey DM et al Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J Antimicrob Chemother 1988; 22:631–636.

    Article  PubMed  CAS  Google Scholar 

  76. Peters DH, Clissold SP. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44:117–164.

    Article  PubMed  CAS  Google Scholar 

  77. Gustavson LE, Kaiser JF, Mukherjee DX et al. Evaluation of the pharmacokinetic drug interactions between clarithromycin and omeprazole (abstract). Am J Gastroenterol 1994; 89: 1373.

    Google Scholar 

  78. Graham DY, Opekun AR, Klein PD. Clarithromycin for the eradication of Helicobacter pylori. J Clin Gastroenterol 1993; 16: 292–294.

    Article  PubMed  CAS  Google Scholar 

  79. Braegger CP, Nadal D. Clarithromycin and pseudomembranous enterocolitis (letter). Lancet 1994; 343:241–242.

    Article  PubMed  CAS  Google Scholar 

  80. Bell DG, Powell KU, Burridge SM et al. Helicobacter pylori treated with combinations of tripotassium dicitrato bismuth-ate and metronidazole: Efficacy of different treatment regimes and some observations on the emergence of metronidazole resistance. Eur J Gastroenterol Hepatol 1992; 3:819–822.

    Google Scholar 

  81. De Koster E, Burette A, Nyst JF. H. pylori treatment; amoxycillin or bismuth plus nitroimidazole? (abstract). Gastroenterology 1991; 100: A52.

    Google Scholar 

  82. Morgando A, Todros L, Boero M et al Therapy of Helicobacter pylori infection: clinical trials with double and triple pharmacological association. Ital J Gastroenterol 1991; 23(suppl 2): 112.

    Google Scholar 

  83. Grigoriev PV, Ariun LI, Isakov VA. De-Nol plus oxacillin vs. ranitidine and oxacillin in Hp positive duodenal ulcers (abstract). Rev Espan Enferm Dig 1990; 78(suppl 1): 129.

    Google Scholar 

  84. Peyre S, Bologna E, Stroppiana M et al. Eradication rate of Helicobacter pylori with 4 different regimes (abstract). Rev Espan Enferm Dig 1990; 78(suppl 1): 107–108.

    Google Scholar 

  85. Rosario M, Alves I, Martins F et al. Combination of bismuth subcitrate and furazolidone in eradication therapy (abstract). Gastroenterology 1992; 102: A45.

    Google Scholar 

  86. Tuo BG, Li YN, Ye SM. The efficacy of colloidal bismuth subcitrate and furazolidone on Helicobacter pylori (abstract). Eur] Gastroenterol Hepatol 1993; 8(suppl 2): S199.

    Article  Google Scholar 

  87. Logan RPH, Rubio MA, Gummett PA. Omeprazole and amoxycillin suspension for Helicobacter pylori (abstract). Irish J Med Sci 1992; 161(suppl 10): 16.

    Google Scholar 

  88. Labenz J, Stolte M, Domain C et al. Omeprazole plus amoxycillin or clarithromycin for eradication of Hp in DU disease (abstract). Acta Gastro-Enterol Belg 1993; 56(suppl 131): 139.

    Google Scholar 

  89. Mannes GA, Bayerdorffer E, Hele C et al. An increasing dose of omeprazole combined with amoxycillin increases the eradication rate of Helicobacter pylori (abstract). Gastroenterology 1993; 104: A140.

    Google Scholar 

  90. Zala G, Wirth HP, Giezendanner S et al. Omeprazole/ amoxycillin: Impaired eradication of H. pyloriby smoking but not by omeprazole pretreatment (abstract). Gastroenterology 1994; 106: A215

    Google Scholar 

  91. Katelaris PH, Patchett SE, Zhang ZW et al. A randomised prospective comparison of clarithromycin versus amoxycillin in combination with omeprazole for eradication of Helicobacter pylori Aliment Pharmacol Ther 1995; 9:205–208

    Article  PubMed  CAS  Google Scholar 

  92. Schaufelberger HD, Logan HD, Misiewicz JJ et al. The dose and frequency of omeprazole are important in treating H. pylori with dual therapy (abstract). Gastroenterology 1993; 104: A186.

    Google Scholar 

  93. Schaufelberger HD, Logan RPH, Baron JH, Misiewicz JJ. The effect of compliance on H. pylori eradication with dual therapy (abstract). Schweiz Med Wochenschr 1993; 123(suppl 55): 21P.

    Google Scholar 

  94. Mendleson M, Greaves R, Logan RPH et al. Eradication of H. pylori with clarithromycin and omeprazole (abstract). Gut 1992;33(suppl 2):T108.

    Google Scholar 

  95. Chen SP, Xiao SD, Hu FL. Combined omeprazole/antibiotic treatments for eradication of Helicobacterpylori in patients with duodenal ulcer — pilot studies. Eur J Gastroenterol Hepatol 1993; 8(suppl 2): S265.

    Google Scholar 

  96. Marchegiani A, Di Capua F. Combined omeprazole/ azithromycin therapy regime for eradication of Helicobacter pylori. Acta Gastro-Enterol Belg 1993; 56(suppl): 141.

    Google Scholar 

  97. Labenz J, Ruhi GH, Domian C et al. Omeprazole plus roxythromycin for eradication of H. pylori. Acta Gastro-Enterol Belg 1993; 56(suppl): 138.

    Google Scholar 

  98. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol Suppl 1993; 196: 34–37.

    Article  PubMed  CAS  Google Scholar 

  99. Cottrill MRB. The prevalence of Helicobacter pylori infection in patients receiving long-term Lb-receptor antagonists in general practice: clinical and financial consequences of eradication using omeprazole plus amoxycillin or ‘triple therapy’. Br J Med Econ 1994; 7: 35–41.

    Google Scholar 

  100. Bell GD, Powell KU, Burridge SM et al. Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med 1993; 86: 743–750.

    PubMed  CAS  Google Scholar 

  101. Noach LA, Bosma NB, Tytgat GNJ. CBS and clarithromycin: alternative therapy for Helicobacter pylori infection in patients with metronidazole resistant strains? (abstract). 2nd United European Gastroenterology Week, Barcelona 1993; A98.

    Google Scholar 

  102. Logan RP, Gummett PA, Misiewicz JJ et al. One week eradication regimen for Helicobacterpylori. Lancet 1991; 338:1249–1252.

    Article  PubMed  CAS  Google Scholar 

  103. Logan RPH, Gummett RA, Walker MM et al. A three-day eradication regime for Helicobacter pylori (abstract). Ital J Gastroenterol 1991; 23(suppl 2): 111.

    Google Scholar 

  104. Grigoriev PY, Isakov VA, Yakovenko EP, Yakovenko AV. Two different triple therapy regimes for Hp positive duodenal ulcers (abstract). Ital J Gastroenterol 1991; 23(suppl 2): 107–108.

    Google Scholar 

  105. Thijs JC, Van Zwet AA, Moden W et al Short report: Clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. Aliment Pharmacol Ther 1994; 8:131–4

    Article  PubMed  CAS  Google Scholar 

  106. Bell DG, Powell KU, Burridge SM et al Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9:41–46.

    Article  PubMed  CAS  Google Scholar 

  107. Lind T, Veldhuywen van Zanten SJO, Unge P et al. The MACH 1 study: optimal one-week treatment for H. pylori is defined? Gut 1995; 37 (Suppl 1): A4.

    Article  Google Scholar 

  108. Moayyedi P, Axon ATR. Efficacy of a new one week triple therapy regime in eradicating Helicobacter pylori (abstract). Gut 1994;35(suppl 1):F248.

    Google Scholar 

  109. Labenz J, Stolte M, Ruhl GH et al One-week low-dose triple therapy for eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1995; 7:9–11.

    PubMed  CAS  Google Scholar 

  110. Lamouliatte H, Cay la R, Zerbib F, Megraud F. Dual therapy versus triple therapy of Helicobacter pylori eradication (abstract). Gastroenterology 1994; 106: A120.

    Google Scholar 

  111. McCarthy CJ, Collins R, Beattie S et al Short report: treatment of Helicobacter pylori-associated duodenal ulcer with omeprazole plus antibiotics. Aliment Pharmacol Ther 1993; 7: 463–466.

    Article  PubMed  CAS  Google Scholar 

  112. Borody T, Andrews P, Brandi S, Devine M. H. pylori eradication, side effects compliance: 14 days vs 12 day triple therapy. Gastroenterology 1993; 104: A44.

    Google Scholar 

  113. Borody TJ, Andrews P, Shortis NP et al Optimal H. pylori therapy — a combination of omeprazole and triple therapy (abstract). Gastroenterology 1994; 106: A55.

    Google Scholar 

  114. Malanoski GJ, Eliopoulos GM, Ferraro MJ, Moellering RCJ. Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur J Clin Microbiol Infect Dis 1993; 12:131–133.

    Article  PubMed  CAS  Google Scholar 

  115. Powell KU, Bell GD, Bowden A et alHelicobacter pylori eradication therapy: a comparison between either omeprazole or ranitidine in combination with amoxycillin plus metronidazole (abstract). Gut 1994; 35(suppl 5): S16.

    Google Scholar 

  116. Bell DG, Powell KU, Burridge SM et al Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9: 41–46

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hammersmith Hospital, London, UK

    John Calam MD FRCP (Reader in Gastroenterology)

Authors
  1. John Calam MD FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1996 John Calam

About this chapter

Cite this chapter

Calam, J. (1996). Treatment. In: Clinicians’ Guide to Helicobacter pylori . Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-3350-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-3350-8_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-412-74000-8

  • Online ISBN: 978-1-4899-3350-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation